Search & Filter

The FDA plans to complete a safety review of the abortion pill mifepristone by March 2027, which could lead to changes in how the drug is prescribed and distributed nationwide. This review is central to a Louisiana legal challenge against federal regulations allowing remote prescription and mail delivery of abortion pills, with the state's Attorney General arguing the FDA did not adequately assess risks before removing in-person dispensing requirements.

The FDA announced that its safety review of the abortion pill mifepristone will continue into next year, with a report expected by March 2027 before deciding on any new restrictions. This update was provided in response to a federal judge's order in a lawsuit brought by Louisiana challenging the mail delivery of mifepristone as undermining the state's abortion ban.